AKT1 and non-small cell lung carcinoma: We treated each EGFR-mutant NSCLC cell line with the AKT inhibitor, MK2206, using different concentrations of lysine in the culture media (55, 27.5, and 13.75 μM), and the results show that the combination of an AKT inhibitor and lysine reduction significantly enhanced the cytostatic effect in EGFR-mutant NSCLC cell lines (Figure 7A for PC9, Figure 7B for NCI-H1975, Figure 7C for HCC827, and Figure 7D for HCC4006).